Fig. 6.
Overexpression of c-FLIPL confers resistance to anti-DR5 mAb in human glioma cells. (A) Western blot showing high expression of either c-FLIPL or c-FLIPS in T98G.FLIPL-10 and -11, or T98G.FLIPs-5 cells transfected with pCR3.V64-Met-Flag-FLIPL, or pCR3.V62-Met-Flag-FLIPS, respectively, whereas undetectable levels of c-FLIPL and c-FLIPS in parental T98G and its subclones T98G.pCR3-1 and -4 cells transfected with the empty vector. (B–G) Suppression of cytotoxic effects by the treatment with anti-DR5 mAbs and sTRAIL in both T98G.FLIPL and T98G.FLIPS cells, but not in T98G.pCR3 cells. Cells were treated with either sTRAIL (0.04 µg/mL), E11 (0.4 µg/mL), or H48 (0.4 µg/mL) for 48 hours and then were subjected to MTT assay.